Skip to content
Mobidiag
Mobidiag
Enabling faster, more accessible molecular diagnostics
  • Home
  • Solutions
    • Respiratory Infections
    • Gastrointestinal Infections
    • Antimicrobial Resistance Management
    • Healthcare Associated Infections
    • Sepsis
  • Products
    • Coronavirus tests
    • Coronavirus solution
    • Amplidiag® RESP-4
    • Novodiag® COVID-19
    • Amplidiag® COVID-19
    • Mobidiag - Novodiag
    • Novodiag® Solution (CE-IVD)
    • COVID-19
    • C. difficile
    • Bacterial GE+
    • CarbaR+
    • Stool Parasites
    • Mobidiag - Amplidiag
    • Amplidiag® Solution (CE-IVD)
    • Amplidiag Easy
    • RESP-4
    • COVID-19
    • H. pylori+ClariR
    • Bacterial GE
    • CarbaR+VRE
    • CarbaR+MCR
    • Stool Parasites
    • Viral GE
    • C. difficile+027
    • LifeSciences (RUO)
    • S7 Fusion Polymerase™
    • Amplidiag® Multiplex PCR Master Mix
  • News
    • Corporate News
    • In the News
    • Events
    • Blog
  • Literature
    • Publications
    • Posters
    • Presentations
  • Company
    • About Us
    • Quality
    • Management Team
    • Investors
    • Careers
  • Contact
    • Contact Us
    • Worldwide Distributors
  • Log in
  • Log in

Corporate News

Journal of Clinical Microbiology

January 20, 2020

J Clin Microbiol. 2020 Oct, Volume 58, Issue 10
Performance Evaluation of the Novodiag Bacterial GE+ Multiplex PCR Assay

Charly Roy, David Robert, Lucie Bénéjat, Alice Buissonniere, Astrid Ducournau, Francis Mégraud, Emilie Bessede, Delphine Boraud, Philippe Lehours

Learn more about Novodiag®Bacterial GE+  test

Share on: Share on FacebookShare on LinkedinShare on Twitter
Posted in: Publications

Post navigation

← Mobidiag Secures Additional Funding from Business Finland for Rapid Sepsis Diagnostic Test
Development of Novodiag® assay for safe and easy molecular testing of novel coronavirus and influenza viruses →

Mobidiag Logo

Mobidiag (HQ)

Keilaranta 16 A
FIN-02150 Espoo
Finland

+358 10 5050 770
sales@mobidiag.com

Mobidiag France

172 rue de Charonne
Le Dorian B2
75011 Paris
France

+33 1 55 25 17 00
adv@mobidiag.com

Mobidiag UK

Aston Court, Kingsmead Business Park,
Frederick Place, High Wycombe
Buckinghamshire, HP11 1LA
UK
+44 (0) 333 305 7506
sales@mobidiag.com

Mobidiag Sweden

+358 10 5050 770
sales@mobidiag.com

Site map

  • Home
  • Solutions
    • Respiratory Infections
    • Gastrointestinal Infections
    • Antimicrobial Resistance Management
    • Healthcare Associated Infections
    • Sepsis
  • Products
    • Coronavirus solutions
    • Novodiag® Solution (CE-IVD)
      • COVID-19
        • Novodiag COVID-19
        • Amplidiag COVID-19
      • C. difficile
      • Bacterial GE+
      • CarbaR+
      • Stool Parasites
    • Amplidiag® Solution (CE-IVD)
      • COVID-19
      • H. pylori+ClariR
      • Viral GE
      • CarbaR+VRE
      • CarbaR+MCR
      • Stool Parasites
      • Bacterial GE
      • C. difficile+027
    • LifeSciences (RUO)
      • S7 Fusion Polymerase
      • Amplidiag® Multiplex PCR Master Mix
  • Corporate News
    • Corporate News
    • Events
    • Blog
  • Company
    • About Us
    • Quality
    • Management Team
    • Investors
    • Careers
  • Literature
  • Contact
    • Contact Us
    • Worldwide Distributors
  • Client Portal
    • Login or Register
    • Edit My Profile
  • Cookie Policy (EU)

Search

Contact Us

    • Home
    • Solutions
    • Products
    • Corporate News
    • Company
    • Literature
    • Contact
    • Client Portal
    • Cookie Policy (EU)
    • Linkedin
    • Twitter
    • Facebook
    Copyright © Mobidiag Ltd. All Rights Reserved.
    Mobidiag, Novodiag®, Amplidiag® and mNAT® are trademarks or registered trademarks of Mobidiag Oy. Other trademarks mentioned on this website
    are the property of their respective owners. No rights to use any trademarks or logos are granted    .
    Learn more about our Privacy policy.
    Website crafted by Design Reform.
    Top